# Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma

> **NCT06848920** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 20 (estimated)

## Conditions studied

- Differentiated Thyroid Carcinoma (DTC)
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment

## Key facts

- **NCT ID:** NCT06848920
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848920, "Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06848920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*